MedPath

The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity

Recruiting
Conditions
Chronic Kidney Disease
Heart Failure With Preserved Ejection Fraction (HFPEF)
Obesity (Disorder)
Registration Number
NCT07052539
Lead Sponsor
University of Mississippi Medical Center
Brief Summary

This research study wants to learn about Chronic Kidney Disease (CKD) with Obesity, and Heart Failure with preserved Ejection Fraction (HFpEF) and better ways to evaluate these diseases. HFpEF means that the heart is not able to fill properly with blood while it is resting so the amount of blood pumped out to the body is less than it would be if it was filling properly. The study is being done to describe the differences in how the kidneys handle protein and salt in participants with HFpEF and obesity compared to healthy persons.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Adults 18-75 years old
  • Normal kidney function
  • No heart failure
  • BMI 25-30kg/m2
Exclusion Criteria
  • Diagnosis of chronic illness
  • eGFR<60mL/min/1.73m2
  • Pregnancy or breast feeding
  • History of cutaneous or allergic reaction to iodine-based products of contrast dyes
  • Hemoglobin levels <7mg/dL
  • Acute illness or hospitalization event within 3 months
  • Unable to stop NSAIDs
  • Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
  • Current use of nicotine or recreational drugs, chronic drinker

Criteria for Cohort 2: Obese Participants without HFpEF

Inclusion Criteria:

  • Adults 18-75 years old
  • eGFR >= 60 mL/min/1.73m2
  • BMI > 35 kg/m2

Exclusion Criteria:

  • Diagnosis of Heart Failure
  • Diagnosis of chronic illness
  • eGFR<60mL/min/1.73m2
  • Pregnancy or breast feeding
  • History of cutaneous or allergic reaction to iodine-based products of contrast dyes
  • Hemoglobin levels <7mg/dL
  • Acute illness or hospitalization event within 3 months
  • Unable to stop NSAIDs
  • Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
  • Current use of nicotine or recreational drugs, chronic drinker

Criteria for Cohort 3: HFpEF and Obese Participants

Inclusion Criteria:

  • Adults 18-75 years old
  • eGFR >= 60 mL/min/1.73m2
  • BMI > 35 kg/m2
  • Diagnosis of HFpEF (chart diagnosis, LVEF > 55% on echo, H2FPEF score 6-9 or HFA-PEFF score 5 or 6

Exclusion Criteria:

  • NYHA class III/IV
  • Urinary retention screen +
  • Mobility issues
  • History of RRT or kidney transplant
  • Acute illness/hospitalization in the past 3 months
  • History of cancer, chemo, or XRT
  • Pregnant/breastfeeding
  • History of allergies to contrast
  • Hemoglobin < 7
  • Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
  • Unable to stop NSAIDs
  • Current use of nicotine or recreational drugs, chronic drinker

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in measured GFR5 hours
Change in urine sodium excretion5 hours
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

University of Mississippi Medical Center

🇺🇸

Jackson, Mississippi, United States

University of Mississippi Medical Center
🇺🇸Jackson, Mississippi, United States
Tekka Johnson
Contact
601-496-7834
tjohnson23@umc.edu
Marissa C Tio, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.